Top Markets
#1 ADO Protocol ADO Protocol +193.18%
#2 Islamic Coin Islamic Coin +155.35%
#3 GoPlus Security GoPlus Security +43.24%
#4 GAIB AID GAIB AID +24.67%
#5 Casper Network Casper Network +14.30%
#6 Verus Coin Verus Coin +13.64%
#7 o1.exchange o1.exchange +12.71%
#8 SkyAI SkyAI +12.71%
#9 Pons Pons +11.32%
#10 Starpower Starpower +10.96%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Apimeds Pharmaceuticals US, Inc Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc

APUS
Rank in Stocks #33689
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage... Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Share Price
$4.70
Last synced: 2026-08-14
Market Cap
$7.09M
Change (1 day)
-0.21%
Change (1 year)
-70.63%
Country
US
Trade Apimeds Pharmaceuticals US, Inc (APUS)

Category

Healthcare
P/E ratio for Apimeds Pharmaceuticals US, Inc (APUS)
P/E ratio as of 2026 TTM: 0
According to Apimeds Pharmaceuticals US, Inc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Apimeds Pharmaceuticals US, Inc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.